While the addition of COXi to standard chemotherapy failed to improve patient outcomes in NSCLC [26,27,28], their use was associated with longer time to progression in ICI treated melanoma patients [29], and no data in NSCLC patients are currently available. Here, MT-CO1 is linked to melanoma.